US 11,987,641 B2
Anti-PSMA antibodies and uses thereof
Shalom Goldberg, Merion Station, PA (US); Donna Klein, Philadelphia, PA (US); Neeraj Kohli, North Wales, PA (US); Theresa Marie McDevitt, Warminster, PA (US); and Steven J. Orcutt, Eagleville, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Aug. 25, 2022, as Appl. No. 17/895,295.
Claims priority of provisional application 63/237,663, filed on Aug. 27, 2021.
Prior Publication US 2023/0131727 A1, Apr. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/00 (2006.01); A61K 47/68 (2017.01); A61P 35/04 (2006.01); C07K 16/30 (2006.01)
CPC C07K 16/3069 (2013.01) [A61K 47/6869 (2017.08); A61P 35/04 (2018.01); C07K 2317/51 (2013.01); C07K 2317/56 (2013.01); C07K 2317/72 (2013.01); C07K 2317/94 (2013.01)] 27 Claims
 
1. An isolated antibody or an antigen binding fragment thereof that binds prostate specific membrane antigen (PSMA), the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of RYGMH (SEQ ID NO: 4), a HCDR2 comprising the amino acid sequence of LISYDGSNRYYADSVKG (SEQ ID NO: 5), and a HCDR3 comprising the amino acid sequence of ERESSGWFEGYFDY (SEQ ID NO: 6), and a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of GGNNIGSKSVH (SEQ ID NO: 7), a LCDR2 comprising the amino acid sequence of DNSDRPS (SEQ ID NO: 8), and a LCDR3 comprising the amino acid sequence of QVWDSSSDHVV (SEQ ID NO: 9).